Gn001
Phase 1
Gn001 is one of 8 therapeutic programs targeting Refractory B-Cell Non-Hodgkin Lymphoma. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
7 competitors in Refractory B-Cell Non-Hodgkin Lymphoma
#DrugCompanyPhaseTrials
1Pemazyre
IncytePhase 2
Rituxan
RochePhase 1
Gazyva
RochePhase 1
Brukinsa
BBeOne Medicines
Phase 1
Tazverik
EEpizyme, Inc.
Phase 1
MK-1045
Merck & Co.Phase 1
YK012
EExcyte Biopharma Ltd
Phase 1
Gn001
DDepartment of Hematology,Rheumatology and Immunology,Pu'er People's Hospital
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Gn001. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]